GLP-1 and kidney disease wasn't an obvious pairing five years ago. GLP-1 drugs were thought of as weight-loss and glucose-lowering agents. Then the FLOW trial landed in May 2024 with a result that stunned nephrologists: semaglutide reduced major kidney disease events by 24% in patients with type 2 diabetes and chronic kidney disease. The trial was actually stopped early for benefit — an unusual step that regulators only take when the evidence is overwhelming.
This article breaks down FLOW in detail: trial design, the composite endpoint, what the 24% number actually means clinically, how semaglutide compares to (and complements) SGLT2 inhibitors like empagliflozin and dapagliflozin, the proposed renal mechanism, the FDA label expansion that followed, and what this means for nephrology practice in 2026.
TL;DR: The FLOW trial (N=3,533) tested semaglutide 1.0 mg weekly vs placebo in T2D patients with CKD. The primary composite endpoint (kidney failure, ≥50% eGFR decline, kidney/CV death) was reduced 24%. Trial stopped early for efficacy. FDA expanded semaglutide's label for CKD in T2D. GLP-1s and SGLT2 inhibitors are now considered complementary — many patients should be on both.
What Is Diabetic Kidney Disease?
Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD) worldwide. Roughly 30–40% of people with type 2 diabetes develop some form of kidney damage during their lifetime. Mechanisms include:
- Glomerular hyperfiltration from chronic hyperglycemia
- Albuminuria as glomerular filtration barriers fail
- Inflammation and fibrosis in kidney tissue
- Vascular damage from coexisting hypertension
Before 2020, ACE inhibitors and ARBs were the mainstay of DKD treatment. Then SGLT2 inhibitors arrived (CREDENCE, DAPA-CKD, EMPA-KIDNEY) and became a second pillar. FLOW makes GLP-1 agonists the third pillar.
The FLOW Trial Design
FLOW (Perkovic et al., NEJM, 2024) was a double-blind, placebo-controlled Phase 3 outcomes trial.
- N = 3,533 patients
- Population: Adults with T2D and CKD (eGFR 50–75 with UACR 300–5000, OR eGFR 25–<50 with UACR 100–5000)
- Intervention: Semaglutide 1.0 mg subcutaneous weekly vs placebo
- Median follow-up: ~3.4 years
- Stopped early in October 2023 (published 2024) because pre-specified efficacy thresholds were crossed
Primary composite endpoint: Time to first occurrence of:
- Onset of persistent ≥50% eGFR reduction
- Onset of persistent eGFR <15 (kidney failure)
- Initiation of chronic kidney replacement therapy
- Death from kidney disease
- Death from cardiovascular causes
The Results
Primary endpoint reduced by 24% (HR 0.76, 95% CI 0.66–0.88, p=0.0003).
Specifically:
- Major kidney outcomes (kidney-specific components): HR 0.79 — 21% reduction
- Annual eGFR slope: Less decline in semaglutide group (slope difference ~1.16 mL/min/1.73 m²/year)
- CV death: HR 0.71 — 29% reduction
- All-cause mortality: HR 0.80 — 20% reduction
The results were highly consistent across subgroups: younger vs older, higher vs lower baseline eGFR, with or without baseline SGLT2 inhibitor use.
Number needed to treat (NNT): Approximately 20 patients over ~3 years to prevent one primary endpoint event. That's an excellent NNT for a chronic disease trial.
Comparison to SGLT2 Inhibitors
SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) have also transformed DKD treatment. Here's how they compare:
| Trial | Drug | Kidney Endpoint Reduction | Population |
|---|---|---|---|
| CREDENCE | Canagliflozin | 30% | T2D + CKD + albuminuria |
| DAPA-CKD | Dapagliflozin | 39% | CKD ± diabetes |
| EMPA-KIDNEY | Empagliflozin | 28% | Broader CKD |
| FLOW | Semaglutide | 24% | T2D + CKD |
The headline numbers aren't directly comparable (different endpoints, populations, durations), but they're in the same ballpark. Importantly, in FLOW, ~15% of patients were already on SGLT2 inhibitors at baseline, and the semaglutide benefit held in that subgroup — suggesting the two drug classes are complementary, not redundant.
Mechanistic rationale for combination:
- SGLT2 inhibitors reduce glomerular hyperfiltration via tubuloglomerular feedback
- GLP-1 drugs reduce inflammation, blood pressure, and weight
- Together they address multiple independent pathways
The 2024 KDIGO guidelines now recommend considering both classes in T2D + CKD patients.
Proposed Mechanism: Why Does Semaglutide Help Kidneys?
GLP-1 receptors are expressed in kidney tissue, though at lower density than in pancreas and brain. Proposed mechanisms include:
- Blood pressure reduction (~2–5 mmHg systolic) — mild but meaningful for kidneys
- Weight loss — reduces glomerular hyperfiltration in obesity
- Anti-inflammatory effects — reduced IL-6, TNF-α, CRP
- Reduced albuminuria independent of BP and glucose
- Direct podocyte protection — suggested by preclinical work
- Improved glycemic control — though SUSTAIN-6 showed renal benefit independent of HbA1c
The effect is likely multifactorial rather than a single pathway.
What the Clinical Trials Show
Beyond FLOW, kidney endpoints have been secondary in multiple GLP-1 trials:
- SUSTAIN-6: Secondary kidney endpoint (new or worsening nephropathy) reduced 36% with semaglutide
- LEADER (liraglutide): Similar reduction of 22%
- REWIND (dulaglutide): Kidney composite reduced 15%
- AWARD-7: Dulaglutide slowed eGFR decline in T2D with moderate-to-severe CKD
- SELECT: Showed CV benefit in cardiovascular prevention population
FLOW is distinctive in being the first GLP-1 trial with kidney disease as the primary endpoint — and the first stopped early for kidney benefit.
FDA Label Expansion
In January 2025, the FDA expanded semaglutide's (Ozempic's) label to include reduction in the risk of kidney disease progression, kidney failure, and CV death in T2D + CKD patients — based on FLOW. Novo Nordisk has not sought a separate kidney indication for Wegovy (the higher-dose obesity formulation), but clinicians frequently extrapolate.
Connection to Gene Editing
Diabetic kidney disease is ultimately a progressive tissue-injury process driven by glucose toxicity, oxidative stress, and fibrosis — closely linked to the hallmarks of aging. Gene editing for kidney disease is early but active: APOL1 variants (which cause disproportionate kidney disease in African-ancestry populations) are a target for base editing programs at Verve and others. See our base editing primer for the technology, and how GLP-1s work for the pharmacology comparison.
Frequently Asked Questions
Does Ozempic help kidneys even without diabetes?
FLOW enrolled only T2D patients. Whether the benefit extends to non-diabetic CKD is untested. Trials are being planned.
Should I take Ozempic and Jardiance together?
Many nephrologists now do prescribe both in T2D + CKD. Consult your physician — co-prescription is supported by KDIGO 2024 guidelines.
Does Wegovy (higher dose semaglutide) help kidneys more?
Unknown — FLOW used the 1.0 mg T2D dose, not 2.4 mg. Effect may be similar or larger at higher doses, but no direct data yet.
What if my eGFR is already very low?
FLOW enrolled patients with eGFR as low as 25. Semaglutide doesn't require dose adjustment for renal function. Patients on dialysis weren't studied.
Does tirzepatide also protect kidneys?
SURPASS-4 showed kidney endpoint improvement, but no dedicated FLOW-equivalent trial has been completed for tirzepatide. One is underway.
Further Learning
- How GLP-1 Drugs Work: Ozempic Explained
- Semaglutide vs Tirzepatide: Mechanism Deep Dive
- Hallmarks of Aging Explained
⚕️ This article is for educational purposes only and does not constitute medical advice. Consult your physician before making decisions about GLP-1 medications.
